Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Explore how Otezla (apremilast) impacts reproductive health, including considerations for pregnancy, breastfeeding, and male fertility. Get essential guidance for family planning and safe medication use while managing chronic inflammatory conditions.
For individuals managing chronic inflammatory conditions like psoriasis and psoriatic arthritis, medication is often a crucial part of daily life. Otezla (apremilast) is a commonly prescribed oral medication that has significantly improved the quality of life for many patients. However, when considering family planning, pregnancy, or breastfeeding, understanding how any medication, including Otezla, might affect reproductive health becomes paramount. This comprehensive guide aims to shed light on the considerations surrounding Otezla and its potential impact on fertility, pregnancy, and breastfeeding, empowering you with the knowledge to have informed discussions with your healthcare provider.
Before delving into its reproductive health implications, it's important to understand what Otezla is and how it works.
Otezla is the brand name for the drug apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor. Unlike some other treatments for inflammatory conditions that are biologics (injected medications), Otezla is a small molecule drug taken by mouth. It works by targeting an enzyme called phosphodiesterase 4, which is involved in the inflammatory process within the body. By inhibiting PDE4, apremilast helps to reduce the production of pro-inflammatory mediators and increase anti-inflammatory mediators, thereby alleviating symptoms of inflammatory diseases.
Apremilast selectively inhibits PDE4, leading to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP levels, in turn, modulate the expression of various inflammatory mediators. Specifically, it reduces the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-23 (IL-23), and other pro-inflammatory cytokines, while increasing the production of the anti-inflammatory cytokine interleukin-10 (IL-10). This dual action helps to dampen the overactive immune response characteristic of conditions like psoriasis and psoriatic arthritis.
Its oral administration and generally favorable safety profile, compared to some other systemic therapies, make it an attractive option for many patients.
When you're taking a long-term medication, its impact on your reproductive journey, whether you're planning to conceive, are already pregnant, or are breastfeeding, is a critical discussion point with your healthcare team.
Pregnancy is a period of significant physiological changes, and the safety of medications during this time is a primary concern. The available data on Otezla use during pregnancy is somewhat limited, as clinical trials typically exclude pregnant individuals. Animal studies have provided some insights, but these do not always directly translate to human experience.
In animal reproduction studies, oral administration of apremilast to pregnant rats and rabbits during organogenesis resulted in increased post-implantation loss (a measure of embryo/fetal deaths) and reductions in fetal body weight at doses higher than the maximum recommended human dose (MRHD) on a body surface area (mg/m²) basis. In rabbits, minor skeletal variations were also observed. These findings suggest a potential for adverse effects on fetal development at high doses.
However, it's crucial to note that these were animal studies, and the doses used were significantly higher than those typically prescribed to humans. Human data from observational studies and post-marketing reports are still accumulating. Currently, there are no adequate and well-controlled studies of Otezla in pregnant women. Therefore, Otezla is generally recommended to be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
To gather more information on the effects of Otezla during pregnancy, a pregnancy exposure registry has been established. Pregnancy registries are vital for collecting data on medication use during pregnancy and monitoring pregnancy outcomes. This information helps healthcare providers and regulatory bodies better understand the risks and benefits of specific medications when used by pregnant individuals. If you become pregnant while taking Otezla, or are considering it, your doctor may recommend enrolling in such a registry. This participation is voluntary and contributes invaluable data to medical science.
If you are a woman of childbearing potential and are considering pregnancy, or if you become pregnant unexpectedly while on Otezla, it is imperative to speak with your doctor immediately. They will evaluate your individual situation, considering the severity of your underlying condition, the potential risks of continuing Otezla, and the risks associated with discontinuing treatment. For some, stopping Otezla might lead to a flare-up of their condition, which could also pose risks to pregnancy. Your doctor can help you weigh these factors and discuss alternative treatment options that may be safer during pregnancy, or guide you on the safest way to manage your condition.
For new mothers, the decision of whether to breastfeed while taking medication is another significant concern. The key questions revolve around whether the drug passes into breast milk and, if so, what potential effects it might have on the nursing infant.
Limited data exists on the presence of apremilast in human milk. However, animal studies have shown that apremilast and its metabolites are excreted in the milk of lactating rats. While animal data doesn't always directly predict human outcomes, it suggests a potential for apremilast to be present in human breast milk.
Because of the potential for serious adverse reactions in a breastfed infant from Otezla, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. The potential risks to an infant could include side effects similar to those experienced by adults taking the medication, although the exact impact on developing infants is not fully known due to limited research.
Similar to pregnancy, if you are breastfeeding or planning to breastfeed while on Otezla, a thorough discussion with your healthcare provider is essential. Your doctor will help you assess the risks and benefits, considering your health needs, the infant's health, and alternative feeding options. They may recommend discontinuing Otezla, temporarily interrupting breastfeeding, or exploring other medications for your condition that have a more established safety profile during lactation.
While much of the focus on reproductive health often centers on women, it's also important to consider the potential impact of medications on male fertility and reproductive health. For men taking Otezla, concerns about its effects on sperm quality or the ability to father children are natural.
There is currently no evidence to suggest that Otezla (apremilast) negatively impacts male fertility or sperm quality in humans. Clinical trials and post-marketing surveillance have not reported male infertility as a side effect of Otezla. Animal studies also have not indicated any adverse effects on male reproductive organs or fertility at doses relevant to human exposure.
If you are a male patient taking Otezla and you and your partner are planning a pregnancy, it is generally considered safe to continue Otezla based on current knowledge. However, it is always best practice to discuss any medications you are taking with your doctor, especially when planning a family. This ensures all aspects of your health and potential interactions are considered, providing you and your partner with peace of mind.
Due to the potential risks observed in animal studies and the limited human data on Otezla during pregnancy, women of childbearing potential are generally advised to use effective contraception during treatment with Otezla. This recommendation helps prevent unintended pregnancies and minimizes potential exposure of a fetus to the drug.
Using a reliable method of birth control is crucial for individuals on Otezla who are sexually active and do not wish to become pregnant. Your doctor can help you choose the most appropriate and effective contraceptive method for your individual circumstances, taking into account your medical history and lifestyle.
Before starting Otezla, or at any point during treatment, discuss your family planning goals and contraception needs with your doctor. They can provide guidance on various birth control options, including hormonal methods (pills, patches, rings, injections, implants), intrauterine devices (IUDs), and barrier methods, and help you select one that is safe and effective for you.
Open and honest communication with your healthcare provider is the cornerstone of safe and effective medication management, especially concerning reproductive health. Here are key instances when you should consult your doctor:
If you are a woman of childbearing potential, or a man planning to father children, discuss your family planning intentions with your doctor before starting Otezla. This allows for proactive planning and consideration of all potential factors.
Contact your doctor immediately if you suspect or confirm pregnancy while taking Otezla. They will help you weigh the risks and benefits of continuing the medication versus discontinuing it, and discuss enrollment in a pregnancy registry.
If you are considering breastfeeding while on Otezla, or if you are already breastfeeding and need to start Otezla, consult your doctor. They can provide personalized advice based on the latest available information and your specific situation.
Any concerns you have regarding Otezla and your fertility, sexual health, or reproductive plans should be discussed with your doctor. They are the best resource for accurate information and personalized medical advice.
Here are some frequently asked questions regarding Otezla and reproductive health:
Based on current clinical data and animal studies, there is no evidence to suggest that Otezla directly affects a woman's ability to conceive. However, if you are having difficulty conceiving, it's important to discuss all your medications and health conditions with your doctor, as other factors may be at play.
Otezla is generally not recommended during pregnancy unless the potential benefits clearly outweigh the potential risks to the fetus. Animal studies showed adverse effects at higher doses, and human data is limited. Always consult your doctor immediately if you are pregnant or planning to become pregnant while on Otezla.
Yes, based on current evidence, there is no indication that Otezla negatively affects male fertility or sperm quality. Men taking Otezla can typically plan to father children without concerns related to the medication itself. However, a discussion with your doctor is always recommended.
If you are planning to get pregnant, schedule a pre-conception counseling appointment with your doctor. Discuss all medications you are taking, including Otezla. Your doctor can help you evaluate your treatment plan, discuss potential risks, and explore alternative therapies if necessary, to ensure the safest possible outcome for you and your baby.
Depending on your specific condition and its severity, your doctor may discuss alternative treatment options that have more established safety profiles during pregnancy or breastfeeding. These might include certain topical treatments, phototherapy, or other systemic medications. The best course of action will always be individualized to your needs.
Otezla (apremilast) is an effective treatment for several chronic inflammatory conditions, but like all medications, its use requires careful consideration, especially when it comes to reproductive health. While current data suggests no direct impact on male fertility, women of childbearing potential must be vigilant about contraception, and both pregnant and breastfeeding individuals should engage in thorough discussions with their healthcare providers. The decision to continue, modify, or discontinue Otezla during family planning, pregnancy, or breastfeeding should always be made in close consultation with your doctor, weighing the benefits of treatment against any potential risks. Your healthcare team is your best resource for personalized advice and ensuring the safest path forward for your health and your family.
Sleeping tablets can help manage insomnia and sleep disorders when used correctly. This guide explains types, benefits, risks, and safe usage tips for better sleep health.
April 11, 2026
Explore the short-term and long-term effects of Adderall on the brain, including its uses, side effects, risks of misuse, and the importance of medical supervision for safe and effective treatment.
April 1, 2026
Curious if Pepto-Bismol can help your stomach after drinking? We explore the potential risks and what the research says about mixing Pepto-Bismol and alcohol, plus safer alternatives for hangover relief.
April 1, 2026